PhD Candidate –DCS Augmented Neurofeedback in Adult ADHD
Thompson Brain & Mind Healthcare (TBMH), in collaboration with the Australian National University (ANU) is leading a randomised control trial investigating whether D-cycloserine (DCS), a partial NMDA receptor agonist, can augment learning-dependent neuroplasticity during 19-channel Z-score neurofeedback (NF) in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
The study uses a double-blind randomised controlled trial comparing Z-score NF combined with DCS versus NF with placebo, alongside an observational stimulant-medication comparison group. Outcomes include ADHD symptom severity, quantitative EEG biomarkers, neurofeedback learning curves, and neurocognitive performance.
The PhD candidate will work within a multidisciplinary clinical research team and will focus on the neurophysiological and cognitive mechanisms underpinning treatment response.
Research Aims of the PHD
The overarching aim of the PhD is to determine whether pharmacological facilitation of NMDA-dependent plasticity enhances neurofeedback learning and clinical outcomes in adult ADHD.

Key Responsibilities
Under supervision, the PhD candidate will:
Candidate Requirements
Essential:
Desirable
Local And Enrolement
Scholarship and Support
Application Process
Applicants should submit:
Not the right position for you? Feel free to share the link to someone you might know.
Thompson Brain & Mind Healthcare (TBMH), in collaboration with the ANU College of Science & Medicine, is pleased to announce a fully funded PhD scholarship opportunity in adolescent mental health.
Applicants should have a background in mental health, psychology, education/teaching, or medicine, and hold a Bachelors degree with First Class Honours (or equivalent).